Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dyadic International Debt-to-Asset Historical Data
* Premium members only.
The historical data trend for Dyadic International's Debt-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DYAI vs EXOZ, INMB, FLNA: Debt-to-Asset Comparison
For the Biotechnology subindustry, Dyadic International's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dyadic International Debt-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dyadic International's Debt-to-Asset distribution charts can be found below:
* The bar in red indicates where Dyadic International's Debt-to-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dyadic International (DYAI) has a Debt-to-Asset of 0.77 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Dyadic International and its competitors.
Is Dyadic International's Debt-to-Asset too high?
Dyadic International's current Debt-to-Asset is 0.77. Overall, Dyadic International has a GF Score™ of 42/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dyadic International's Debt-to-Asset compare to EXOZ and INMB?
Dyadic International's Debt-to-Asset of 0.77 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Dyadic International and its competitors. Dyadic International's current Debt-to-Asset is 0.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dyadic International stock overvalued right now?
Based on GuruFocus' analysis, Dyadic International (DYAI) is currently considered Fairly Valued. The stock's GF Value™ is $0.73, compared to a current price of $0.78 — trading 6.8% above its estimated fair value. The current Debt-to-Asset is 0.77. Dyadic International's overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Dyadic International (DYAI), the current Debt-to-Asset is 0.77 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dyadic International (DYAI) Overvalued in 2026?
Based on GuruFocus' analysis, Dyadic International stock appears to be overvalued.
The current stock price of $0.78 is trading 6.8% above its estimated GF Value™ of $0.73.
GuruFocus considers Dyadic International to be Fairly Valued.
Key valuation signals for DYAI:
Debt-to-Asset: 0.77
GF Value™: $0.73 vs. price of $0.78 (6.8% above fair value)
No single metric tells the full story. See the DYAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
42GF Score
Get the complete analysis for DYAI
Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DYAI has been successfully added to your 
